Open AccessChanges in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
Author(s) -
Patrick R. Lawler,
Hongyan Liu,
Claudia Frankfurter,
Leif E. Lovblom,
Yuliya Lytvyn,
Dylan Burger,
Kevin D. Burns,
Davor Brinc,
David Z.I. Cherney
Publication year - 2021
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc20-2265
Subject(s) - medicine , dapagliflozin , kidney disease , diabetes mellitus , type 2 diabetes , renal function , natriuretic peptide , heart failure , biomarker , canagliflozin , endocrinology , chemistry , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom